CCR2 on CD14+CD16+ monocytes is a biomarker of HIV-associated neurocognitive disorders

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 3, 2014, Pages

  Williams, Dionna W ^a   Byrd, Desiree ^b   Rubin, Leah H ^c   Anastos, Kathryn ^a   Morgello, Susan ^b   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD14 ANTIGEN; CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR2; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CD4 LYMPHOCYTE COUNT; CELL MIGRATION; CLINICAL EVALUATION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIAPEDESIS; DISEASE SEVERITY; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; VIRUS LOAD;

EID: 84929604722     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000036     Document Type: Article

References (31)

1. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012;206:275-282.
2. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799.
3. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology 2010;75:2087-2096.
4. Heaton R, Franklin D, Ellis R, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3-16.
5. Williams DW, Eugenin EA, Calderon TM, Berman JW. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 2012;91:401-415.
6. Ellery PJ, Tippett E, Chiu YL, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007;178:6581-6589.
7. Shiramizu B, Ananworanich J, Chalermchai T, et al. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neurovirol 2012;18:69-73.
8. Cinque P, Vago L, Mengozzi M, et al. Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 1998;12:1327-1332.
9. Kamat A, Lyons JL, Misra V, et al. Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr 2012;60:234-243.
10. Volpe S, Cameroni E, Moepps B, Thelen S, Apuzzo T, Thelen M. CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. PLoS ONE 2012;7:e37208.
11. Carter PH. Progress in the discovery of CC chemokine receptor 2 antagonists, 2009-2012. Expert Opin Ther Pat 2013;23:549-568.
12. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 2004;61:546-551.
13. Ryan E, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004;62:957-962.
14. Byrd DA, Robinson-Papp J, Mindt MR, et al. Isolating cognitive and neurologic HIV effects in substance-dependent, confounded cohorts: a pilot study. J Int Neuropsychol Soc 2013;19:463-473.
15. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004;26:759-778.
16. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Neurology 1996;47:1247-1253.
17. McArthur J, Smith B. Neurologic complications and considerations in HIV-infected persons. Curr Infect Dis Rep 2013;15:61-66.
18. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182.
19. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013;56:1004-1017.
20. Morley D, McNamara P, Kennelly S, McMahon G, Bergin C. Limitations to the identification of HIV-associated neurocognitive disorders in clinical practice. HIV Med 2013;14:497-502.
21. Winston A, Vera JH. Can antiretroviral therapy prevent HIV-associated cognitive disorders? Curr Opin HIV AIDS 2014;9:11-16.
22. Manji H, Jäger HR, Winston A. HIV, dementia and anti-retroviral drugs: 30 years of an epidemic. J Neurol Neurosurg Psychiatry 2013;84:1126-1137.
23. González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005;5:69-81.
24. Gelman BB, Lisinicchia JG, Morgello S, et al. Neuro-virological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr 2013;62: 487-495.
25. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009;15: 360-370.
26. Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005; 64:529-536.
27. Roc AC, Ances BM, Chawla S, et al. Detection of human immunodeficiency virus induced inflammation and oxidative stress in lenticular nuclei with magnetic resonance spectroscopy despite antiretroviral therapy. Arch Neurol 2007;64:1249.
28. Harezlak J, Buchthal S, Taylor M, et al. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011;25:625-633.
29. Desplats P, Dumaop W, Smith D, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013;80:1415-1423.
30. Hearps A, Martin G, Rajasuriar R, Crowe S. Inflammatory co-morbidities in HIV1 individuals: learning lessons from healthy ageing. Curr HIV/AIDS Rep 2014;11:1-15.
31. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27:1387-1395.